Fidaxomicin is a recently approved antibiotic with a confusing history dating back to its original isolation in 1975. Fidaxomicin is the major analogue of a family of macrocyclic lactones isolated independently by three different groups from cultures belonging to three different genera (Actinoplanes, Dactylosporangium and Micromonospora) known as lipiarmycin A3, tiacumicin B and clostomicin B1, respectively. Fidaxomicin is a narrow spectrum antibiotic that works by inhibiting bacterial RNA polymerase and demonstrates excellent activity against Gram positive bacteria, notably Clostridium difficile. Fidaxomicin acts in the gastrointestinal tract without undue disruption to gut microbial flora.
See how others have used Fidaxomicin (CAS 873857-62-6). Click on the entry to view the PubMed entry .
PMID: # 30052178 Skinner, K. et al. 2018. J. Med. Microbiol. 67: 1402-1409.
PMID: # 28533232 Corbett, D. et al. 2017. Antimicrob. Agents Chemother.
PMID: # 25652750 Corbett, D. et al. 2015. J. Antimicrob. Chemother. 70: 1751-6.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.